← boardnext 2026-12next 2026-12next 2027-02next 2027-07
KRYS
Krystal Biotech, Inc.distress 1/10 · well-funded / low risk$330.66-2%today-13% from 52w high
Lead: Cancer
Revenue
$116M
Liquidity
$695M
Runway
—
Shares 1y
+2%
Price & events
+14.4% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.8%
1D
-3.3%
1W
-2.8%
1M
+23.4%
3M
+17.5%
6M
+115.8%
1Y
+59.6%
2Y
+445.6%
5Y
+456.5%
All
Overview
- Market Cap
- $9.75B
- Volume
- 16.18K
- 52 Week Range
- $135 – $378
- Total Shares
- 29.48M
- Float Shares
- 23.42M
- Short %
- 19.59%
- % Held by Insiders
- 10.97%
- % Held by Institutions
- 99.55%
- RVOL
- 0.04x
- Beta
- 0.50
Pipeline stages · 6 programs
KB803
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
KB801
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
KB707, Pembrolizumab (KEYTRUDA®), Chemotherapy
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
KB707, Opdualag, KEYTRUDA ®( Pembrolizumab)
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
KB304, 0.9% Normal Saline (NS)
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
KB408 (Nebulization)
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 6 trials · 4 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-12 Estimated 50% readout ~2027-02-14 | Phase 3 | KB803 | Dystrophic Epidermolysis Bullosa, DEB - Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa, Dominant Dystrophic Epidermolysis Bullosa | — | recruiting |
| 2026-12 Estimated 50% readout ~2027-01-15 | Phase 1/2 | KB801 | Neurotrophic Keratitis | — | recruiting |
| 2027-02 Estimated 50% readout ~2027-03-18 | Phase 1/2 | KB707, Pembrolizumab (KEYTRUDA®), Chemotherapy | Lung Cancer, Non-small Cell, Lung Cancer Metastatic, Solid Tumor, Adult, Advanced Cancer, Lung Cancer (NSCLC) | — | recruiting |
| 2027-07 Estimated 50% readout ~2027-08-15 | Phase 1/2 | KB707, Opdualag, KEYTRUDA ®( Pembrolizumab) | Cancer, Melanoma Stage III, Melanoma Stage IV, Cutaneous Melanoma | — | recruiting |
| 2025-12 | Phase 1 | KB408 (Nebulization) | Alpha 1-Antitrypsin Deficiency | 15 | recruiting |
Show all 6 trials · 1 more ▾
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2025-07 | Phase 1/2 | KB304, 0.9% Normal Saline (NS) | Wrinkles in Decolletage, Pigmentation, Décolleté Wrinkles | 19 | active not recruiting |
Catalyst news & presentations · 6
- 2026-08-03Estimated 45%earningsEarningsEarnings releaseyahoo
- January 8, 2026readoutPhase 1KB407 · Positive interim clinical update from CORAL-1 study confirming wild-type CFTR deliverySEC 8-K
- July 24, 2025readoutPhase 1KB304 · Positive safety and efficacy results for Phase 1 studySEC 8-K
- July 9, 2025trial initiationsecondaryPhase 1/2KB801 · First patient dosed in Phase 1/2 trialSEC 8-K
- June 2, 2025conferencedata presentationsecondaryPhase 1/2KB707 · Monotherapy cohort results from Phase 1/2 trial presented at ASCO 2025.SEC 8-K
- May 5, 2025conferencedata presentationsecondaryKB801 · Poster on topical gene therapy vector showing sustained NGF expression.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $362 (+9% upside) · 9 analysts
- 2026-07-14B of A SecuritiesBuy
- 2026-06-18TD CowenBuy
- 2026-06-16HC Wainwright & Co.Buy
- 2026-06-01HC Wainwright & Co.Buy
- 2026-05-22HC Wainwright & Co.Buy
- 2026-05-18HC Wainwright & Co.Buy
Competitors — Cancer
- ABBVAbbVie Inc.$451.1B · D2
- MRKMerck & Co., Inc.$318.8B · D3
- NVSEFNOVARTIS AG$292.0B · D3
- AMGNAMGEN INC$195.4B · D3
- PFEPFIZER INC$142.2B · D3
- BNTXBioNTech SE$23.1B · D1
- OLMAOlema Pharmaceuticals, Inc.$990M · D4
- CELG-RIBRISTOL MYERS SQUIBB CO$241M · D2
- BCYCBICYCLE THERAPEUTICS PLC$124M · D4
- AZNASTRAZENECA PLC— · D3
Recent news
- 2026-07-21Krystal Biotech, Inc. (KRYS) Q1 2024 Earnings Report - Results, Call & Slides - TipRanks
- 2026-07-21Krystal Biotech (KRYS) Joins S&P MidCap 400 Amid Index Changes - GuruFocus
- 2026-07-21Krystal Biotech, Inc. (KRYS) Q3 2024 Earnings Report - Results, Call & Slides - TipRanks
- 2026-07-20Krystal Biotech Set to Enter S&P MidCap 400 as Two Join - Stock Titan
- 2026-07-20Krystal Biotech Set to Join S&P MidCap 400; Tutor Perini and V2X to Join S&P SmallCap 600 - Yahoo Finance
- 2026-07-20Krystal Biotech, Inc. (KRYS) Stock Analysis: Exploring a $10 Billion Valuation and Strategic Growth in Genetic Medicine - DirectorsTalk Interviews
- 2026-07-19(KRYS) and the Role of Price-Sensitive Allocations - Stock Traders Daily
- 2026-07-19KRYS Jumps As Wall Street Hikes Price Targets On Vyjuvek Momentum - StocksToTrade
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.